A Sharply Defined Pattern of Central Retinal Thinning
Think of a large, evenly lit mural on a wall, where a single tidy square has been repainted in flat grey, its edges razor-straight, while everything else around it remains as vivid as before. Central areolar choroidal dystrophy leaves a rather similar impression on a retinal examination — a sharply defined zone of atrophy sitting directly beneath the macula, with the surrounding retina and choroid remaining largely intact. It's that crisp, clean boundary, more than anything else, that tends to catch a specialist's eye first.
Tanzanian patients most often present with this condition in their thirties or forties, frequently after a routine check turned up a pale patch with an oddly precise edge, something a local ophthalmologist rightly flagged as out of step with ordinary ageing at that stage of life.
The change tends to be subtle enough that people only piece it together afterward — text they once read easily has become a strain over a year or two, or they've picked up the habit of turning their head slightly so a face lands more to the side of their vision than dead centre. A sharply bordered dark patch settles into the very middle of their sight as the condition advances, yet finding a doorway or navigating a busy street stays entirely unaffected, since only that narrow central window is involved and low-light vision is left completely untouched.
A fault in the PRPH2 gene explains most confirmed cases — this gene normally builds a structural protein that photoreceptor cells need to keep their shape and carry out their job. Once that protein fails, three closely linked layers beneath the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors sitting above them — deteriorate together, but the process stays locked within that one narrow patch rather than spreading. It's generally inherited as a dominant trait, turning up across successive generations.
What stands out on examination is how unusually sharp the edge of the atrophic zone is, almost as if it had been outlined with a ruler, and fundus autofluorescence is what lets us map that boundary with real accuracy. OCT tells us how much photoreceptor tissue survives right at the margin, often the single most useful detail for planning ahead, and a near-normal ERG reassures us that the process has stayed contained rather than reaching further. A PRPH2 genetic test rounds off the diagnostic work.
Rather than following one fixed schedule, we let the pace of the atrophic patch itself guide how we plan care, tracked through repeat imaging spaced over time rather than judged from a single visit. Patients who meet the criteria are considered for regenerative stem cell therapy aimed at protecting the retina still functioning around the edges of the affected zone, and as the central blind spot becomes more defined, we talk through low-vision approaches suited to that individual pattern of loss.
Not in the slightest — it actually lines up with what we'd expect. Because the disease is confined to a small central zone and leaves the rod cells responsible for night vision alone, seeing in the dark generally stays reliable even as reading and recognising faces grow harder.
Not really a fixed one — some people barely change across a decade of follow-up, while others progress more noticeably within a few years. That unpredictability is exactly why we track things through repeated imaging rather than guessing at a growth rate.
They can look strikingly alike under the microscope, but the underlying cause and the age they start are quite different — yours from an inherited gene fault arriving decades early, hers from age-related changes building up much later. Genetic testing and the age of onset settle which is which.
Unlikely for most people — everyday mobility and orientation tend to stay solid, since the condition remains boxed into a defined central area rather than reaching into the broader field of vision that guides movement.